VEGFR
All Product Categories
-
VEGFR Inhibitors
(337)
View all products
-
VEGFR Agonists
(5)
View all products
-
VEGFR Antagonists
(4)
View all products
-
VEGFR Activators
(7)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Ligands
(3)
View all products
-
VEGFR Related Products (403)
Related Products (403)
-
Isomangiferin
0 ImagesIsomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.
-
Lenvatinib-d4
0 ImagesSynonyms: E7080-d4; MK-7902-d4
-
VGX-100
0 ImagesCat. No.: HY-P990675Purity: 99.54%
-
Albendazole (Standard)
0 ImagesSynonyms: SKF-62979 (Standard)Albendazole (Standard) is the analytical standard of Albendazole. This product is intended for research and analytical applications. Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells.
-
Pamufetinib mesylate
0 ImagesSynonyms: TAS-115 mesylatePamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
-
Theasaponin E1
0 ImagesTheasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections.
-
Axitinib-13C,d3
0 ImagesCat. No.: HY-10065SCAS No.: 1261432-00-1Synonyms: AG-013736-13C，d3Axitinib-13C,d3 is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50 values of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
-
Anti-VEGFB Antibody (CSL346)
0 ImagesCat. No.: HY-P990540Purity: ≥99.0%Synonyms: CSL346; ReflocibartAnti-VEGFB Antibody (CSL346; Reflocibart) is a humanized IgG4κ monoclonal antibody targeting VEGF-B, which binds to VEGF-B with high affinity to reduce its activity. Anti-VEGFB Antibody (CSL346) inhibits ectopic lipid deposition in the kidney, improves the histological manifestations of glomerular injury, and reduces proteinuria in animal models. Anti-VEGFB Antibody (CSL346) can be used in studies related to diabetic nephropathy.
-
5α-Hydroxycostic acid
0 ImagesCat. No.: HY-N2666CAS No.: 132185-83-25α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.
-
10Z-Hymenialdisine
0 ImagesCat. No.: HY-N6794CAS No.: 82005-12-7Synonyms: (Z)-Hymenialdisine; Hymenialdisine10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.
-
Tafetinib
0 ImagesCat. No.: HY-116116CAS No.: 1032265-57-8Synonyms: SIM010603Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.
-
LY3022856
0 ImagesCat. No.: HY-P990620Purity: 98.84%
-
Olinvacimab
0 ImagesCat. No.: HY-P99768CAS No.: 2095504-49-5Synonyms: TTAC-0001; TanibirumabOlinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.
-
Dilpacimab
0 ImagesCat. No.: HY-P99852CAS No.: 1791420-09-1Synonyms: ABT165; PR1283233Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors.
